Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1996 September; 74(6): 961–963.
PMCID: PMC2074723

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.


The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (673K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer. 1993 Jul 15;72(2):394–404. [PubMed]
  • van Breukelen FJ, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A, Dalesio O. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1991;27(12):1627–1629. [PubMed]
  • Calavrezos A, Koschel G, Hüsselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr. 1988 Jul 15;66(14):607–613. [PubMed]
  • Gupta RS. Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies. J Cell Physiol. 1983 Jan;114(1):137–144. [PubMed]
  • Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 1991;28(5):319–330. [PubMed]
  • Krarup-Hansen A. Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer. 1994 Sep;11(3-4):305–308. [PubMed]
  • Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ, Planteydt HT, van Zandwijk N. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1992 May;10(5):824–828. [PubMed]
  • Van Meerbeeck JP. Prognostic factors in malignant mesothelioma: where do we go from here? Eur Respir J. 1994 Jun;7(6):1029–1031. [PubMed]
  • Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc. 1988 Dec;63(12):1234–1244. [PubMed]
  • Rowinsky EK, Donehower RC. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. [PubMed]
  • Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993 Aug;20(4 Suppl 3):1–15. [PubMed]
  • Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994 Feb;12(2):241–248. [PubMed]
  • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. [PubMed]
  • Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol. 1992 Aug;19(4 Suppl 11):64–71. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK